Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
26-28 August, 2025
KY/TN Water Profession...KY/TN Water Professionals
Not Confirmed
Not Confirmed
27-30 July, 2025
Chemicals AmericaChemicals America
Not Confirmed
Not Confirmed
29-31 July, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
26-28 August, 2025
KY/TN Water Profession...KY/TN Water Professionals
Industry Trade Show
Not Confirmed
27-30 July, 2025
Chemicals AmericaChemicals America
Industry Trade Show
Not Confirmed
29-31 July, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint
09 Apr 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/04/09/3058270/0/en/KSQ-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-2-Study-for-KSQ-004EX-a-CRISPR-Cas9-Engineered-Tumor-Infiltrating-Lymphocyte-eTIL-Therapy.html
05 Mar 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/03/05/3037288/0/en/KSQ-Therapeutics-Appoints-Kristen-Hege-M-D-to-its-Board-of-Directors.html
22 Oct 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/10/22/2966785/0/en/KSQ-Therapeutics-Appoints-John-Lepore-M-D-to-its-Board-of-Directors.html
08 Oct 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/en/news-release/2024/10/08/2959551/0/en/KSQ-Therapeutics-Appoints-Anna-Truppel-Hartmann-M-D-as-Chief-Medical-Officer.html
24 Sep 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/09/24/2952011/0/en/KSQ-Therapeutics-Announces-FDA-Clearance-of-IND-Application-for-KSQ-004EX-a-CRISPR-Cas9-Engineered-Tumor-Infiltrating-Lymphocyte-eTIL-Therapy.html
28 Aug 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/08/28/2936872/0/en/KSQ-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences.html
Details:
KSQ-004EX, an eTIL cell therapy in which TIL are edited to inactivate the genes encoding SOCS1 and Regnase-1, is being evaluated for the treatment of advanced solid tumor.
Lead Product(s): KSQ-004EX,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Brand Name: KSQ-004EX
Study Phase: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 09, 2025
Lead Product(s) : KSQ-004EX,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
KSQ Doses First Patient with CRISPR-Based KSQ-004EX eTIL Therapy
Details : KSQ-004EX, an eTIL cell therapy in which TIL are edited to inactivate the genes encoding SOCS1 and Regnase-1, is being evaluated for the treatment of advanced solid tumor.
Product Name : KSQ-004EX
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 09, 2025
Details:
KSQ-001EX consists of TILs in which the SOCS1 gene is inactivated by CRISPR/Cas9 gene editing. It is being evaluated for the treatment of advanced solid tumors including head and neck cancer.
Lead Product(s): KSQ-001EX,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Brand Name: KSQ-001EX
Study Phase: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 06, 2024
Lead Product(s) : KSQ-001EX,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
KSQ Therapeutics Doses First Patient in KSQ-001EX eTIL Therapy Development Program
Details : KSQ-001EX consists of TILs in which the SOCS1 gene is inactivated by CRISPR/Cas9 gene editing. It is being evaluated for the treatment of advanced solid tumors including head and neck cancer.
Product Name : KSQ-001EX
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 06, 2024
Details:
KSQ-004EX, an eTIL cell therapy in which TIL are edited to inactivate the genes encoding SOCS1 and Regnase-1, is being evaluated for the treatment of advanced solid tumor.
Lead Product(s): KSQ-004EX
Therapeutic Area: Oncology Brand Name: KSQ-004EX
Study Phase: IND EnablingProduct Type: Cell and Gene therapy
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 24, 2024
Lead Product(s) : KSQ-004EX
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
KSQ Therapeutics Receives FDA Clearance For CRISPR-Engineered eTIL® Therapy
Details : KSQ-004EX, an eTIL cell therapy in which TIL are edited to inactivate the genes encoding SOCS1 and Regnase-1, is being evaluated for the treatment of advanced solid tumor.
Product Name : KSQ-004EX
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
September 24, 2024
Details:
KSQ-001EX consists of TILs in which the SOCS1 gene is inactivated by CRISPR/Cas9 gene editing. It is being evaluated for the treatment of advanced solid tumors including head and neck cancer, melanoma & lung cancer.
Lead Product(s): KSQ-001EX
Therapeutic Area: Oncology Brand Name: KSQ-001EX
Study Phase: IND EnablingProduct Type: Cell and Gene therapy
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 29, 2023
Lead Product(s) : KSQ-001EX
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : KSQ-001EX consists of TILs in which the SOCS1 gene is inactivated by CRISPR/Cas9 gene editing. It is being evaluated for the treatment of advanced solid tumors including head and neck cancer, melanoma & lung cancer.
Product Name : KSQ-001EX
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 29, 2023
Details:
The agreement aims for the development and commercialization of KSQ-4279, a first-in-class, potent, and selective small molecule inhibitor of USP1, in a Phase 1 clinical trial for the treatment of solid tumors.
Lead Product(s): KSQ-4279
Therapeutic Area: Oncology Brand Name: KSQ-4279
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 13, 2023
Details : The agreement aims for the development and commercialization of KSQ-4279, a first-in-class, potent, and selective small molecule inhibitor of USP1, in a Phase 1 clinical trial for the treatment of solid tumors.
Product Name : KSQ-4279
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 13, 2023
Details:
The collaboration aims to expedite the development of KSQ's two lead engineered tumor-infiltrating lymphocyte programs, a single-edit eTIL that deletes the SOCS1 gene, and KSQ-004EX, a dual-edit eTIL that deletes both the SOCS1 and Regnase-1 genes, for solid tumors.
Lead Product(s): KSQ-001EX
Therapeutic Area: Oncology Brand Name: KSQ-001EX
Study Phase: IND EnablingProduct Type: Cell and Gene therapy
Sponsor: CTMC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 09, 2023
Lead Product(s) : KSQ-001EX
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : CTMC
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims to expedite the development of KSQ's two lead engineered tumor-infiltrating lymphocyte programs, a single-edit eTIL that deletes the SOCS1 gene, and KSQ-004EX, a dual-edit eTIL that deletes both the SOCS1 and Regnase-1 genes, for s...
Product Name : KSQ-001EX
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
June 09, 2023
Details:
The expanded collaboration is focused on novel tumor-intrinsic natural killer (NK) and T-cell targets discovery and validation to inform the development of targeted therapies in cancer by using KSQ's proprietary CRISPRomics® platform.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: DiscoveryProduct Type: Undisclosed
Sponsor: Takeda Pharmaceutical
Deal Size: $510.0 million Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration May 17, 2023
Details : The expanded collaboration is focused on novel tumor-intrinsic natural killer (NK) and T-cell targets discovery and validation to inform the development of targeted therapies in cancer by using KSQ's proprietary CRISPRomics® platform.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 17, 2023
Details:
Under the terms of the agreement, acquisition of multiple research-stage DNA damage response (DDR) programs identified using KSQ’s CRISPRomics platform technology will advance identification of novel oncology targets and develop potential first-in-class programs.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: DiscoveryProduct Type: Undisclosed
Sponsor: Ono Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 25, 2023
Details : Under the terms of the agreement, acquisition of multiple research-stage DNA damage response (DDR) programs identified using KSQ’s CRISPRomics platform technology will advance identification of novel oncology targets and develop potential first-in-clas...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 25, 2023
Details:
KSQ-4279 is a first-in-class small molecule targeting USP1, a protein regulating DNA damage response (DDR). USP1 was identified by KSQ's CRISPRomics platform as a novel synthetic lethal target in cancers with certain types of genomic instability.
Lead Product(s): KSQ-4279,Undisclosed
Therapeutic Area: Oncology Brand Name: KSQ-4279
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 12, 2022
Details : KSQ-4279 is a first-in-class small molecule targeting USP1, a protein regulating DNA damage response (DDR). USP1 was identified by KSQ's CRISPRomics platform as a novel synthetic lethal target in cancers with certain types of genomic instability.
Product Name : KSQ-4279
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 12, 2022
Details:
KSQ-4279, a potent and selective USP1 inhibitor, has a unique mode of allosteric binding to USP1 and a high degree of selectivity over other family members, in patients with advanced solid tumors.
Lead Product(s): KSQ-4279,Undisclosed
Therapeutic Area: Oncology Brand Name: KSQ-4279
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 22, 2022
Details : KSQ-4279, a potent and selective USP1 inhibitor, has a unique mode of allosteric binding to USP1 and a high degree of selectivity over other family members, in patients with advanced solid tumors.
Product Name : KSQ-4279
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 22, 2022
ABOUT THIS PAGE